Search
Close this search box.

Cystic Fibrosis

VX18-445-113

STUDY OUTLINE

This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination with tezacaftor (TEZ) and ivacaftor (IVA).

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Currently taking part in VX17-659-105 clinical trial.
  • Aged 12 years or over but only 18 years or over at our site.
  • Diagnosis of Cystic Fibrosis with a homozygous for the F508del (F/F) mutation or heterozygous for the F508del mutation and a minimal function mutation (F/MF).

WHAT'S INVOLVED

  • The total study duration is approximately 100 weeks (96 weeks for the Treatment Period, and 4 weeks for the Safety Follow-up Period). It involves  approximately 13 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and approximately 14 phone calls.

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top